316 related articles for article (PubMed ID: 25241923)
1. Membrane-bound complement regulatory proteins are prognostic factors of operable breast cancer treated with adjuvant trastuzumab: a retrospective study.
Liu M; Yang YJ; Zheng H; Zhong XR; Wang Y; Wang Z; Wang YG; Wang YP
Oncol Rep; 2014 Dec; 32(6):2619-27. PubMed ID: 25241923
[TBL] [Abstract][Full Text] [Related]
2. Downregulation of membrane complement inhibitors CD55 and CD59 by siRNA sensitises uterine serous carcinoma overexpressing Her2/neu to complement and antibody-dependent cell cytotoxicity in vitro: implications for trastuzumab-based immunotherapy.
Bellone S; Roque D; Cocco E; Gasparrini S; Bortolomai I; Buza N; Abu-Khalaf M; Silasi DA; Ratner E; Azodi M; Schwartz PE; Rutherford TJ; Pecorelli S; Santin AD
Br J Cancer; 2012 Apr; 106(9):1543-50. PubMed ID: 22531721
[TBL] [Abstract][Full Text] [Related]
3. Analysis of the level of mRNA expression of the membrane regulators of complement, CD59, CD55 and CD46, in breast cancer.
Rushmere NK; Knowlden JM; Gee JM; Harper ME; Robertson JF; Morgan BP; Nicholson RI
Int J Cancer; 2004 Mar; 108(6):930-6. PubMed ID: 14712499
[TBL] [Abstract][Full Text] [Related]
4. Duration of anti-HER2 blockage therapy may improve survival in HER2 positive metastatic breast carcinoma patients.
Arslan UY; Turker I; Aksoy S; Oksuzoglu B; Helvaci K; Yildirim Ozdemir N; Uyeturk U; Uysal Sonmez O; Budakoglu B; Zengin N
J BUON; 2013; 18(3):585-93. PubMed ID: 24065468
[TBL] [Abstract][Full Text] [Related]
5. Lipoplex mediated silencing of membrane regulators (CD46, CD55 and CD59) enhances complement-dependent anti-tumor activity of trastuzumab and pertuzumab.
Mamidi S; Cinci M; Hasmann M; Fehring V; Kirschfink M
Mol Oncol; 2013 Jun; 7(3):580-94. PubMed ID: 23474221
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of membrane complement inhibitor expression (CD46, CD55, CD59) by siRNA sensitizes tumor cells to complement attack in vitro.
Geis N; Zell S; Rutz R; Li W; Giese T; Mamidi S; Schultz S; Kirschfink M
Curr Cancer Drug Targets; 2010 Dec; 10(8):922-31. PubMed ID: 20879979
[TBL] [Abstract][Full Text] [Related]
7. Systematic immunohistochemical analysis of the expression of CD46, CD55, and CD59 in colon cancer.
Shang Y; Chai N; Gu Y; Ding L; Yang Y; Zhou J; Ren G; Hao X; Fan D; Wu K; Nie Y
Arch Pathol Lab Med; 2014 Jul; 138(7):910-9. PubMed ID: 24978917
[TBL] [Abstract][Full Text] [Related]
8. Levels of cell membrane CD59 regulate the extent of complement-mediated lysis of human melanoma cells.
Brasoveanu LI; Altomonte M; Fonsatti E; Colizzi F; Coral S; Nicotra MR; Cattarossi I; Cattelan A; Natali PG; Maio M
Lab Invest; 1996 Jan; 74(1):33-42. PubMed ID: 8569195
[TBL] [Abstract][Full Text] [Related]
9. Expression of CD46, CD55, and CD59 on renal tumor cell lines and their role in preventing complement-mediated tumor cell lysis.
Gorter A; Blok VT; Haasnoot WH; Ensink NG; Daha MR; Fleuren GJ
Lab Invest; 1996 Jun; 74(6):1039-49. PubMed ID: 8667608
[TBL] [Abstract][Full Text] [Related]
10. Complement activated by chimeric anti-folate receptor antibodies is an efficient effector system to control ovarian carcinoma.
Macor P; Mezzanzanica D; Cossetti C; Alberti P; Figini M; Canevari S; Tedesco F
Cancer Res; 2006 Apr; 66(7):3876-83. PubMed ID: 16585216
[TBL] [Abstract][Full Text] [Related]
11. Clinical outcome in women with HER2-positive de novo or recurring stage IV breast cancer receiving trastuzumab-based therapy.
Rossi V; Nolè F; Redana S; Adamoli L; Martinello R; Aurilio G; Verri E; Sapino A; Viale G; Aglietta M; Montemurro F
Breast; 2014 Feb; 23(1):44-9. PubMed ID: 24210572
[TBL] [Abstract][Full Text] [Related]
12. Expression and modulation of RPE cell membrane complement regulatory proteins.
Yang P; Tyrrell J; Han I; Jaffe GJ
Invest Ophthalmol Vis Sci; 2009 Jul; 50(7):3473-81. PubMed ID: 19168900
[TBL] [Abstract][Full Text] [Related]
13. Cell-surface density of complement restriction factors (CD46, CD55, and CD59): oral squamous cell carcinoma versus other solid tumors.
Ravindranath NM; Shuler C
Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2007 Feb; 103(2):231-9. PubMed ID: 17234541
[TBL] [Abstract][Full Text] [Related]
14. Membrane-bound regulators of complement activation in uveal melanomas. CD46, CD55, and CD59 in uveal melanomas.
Goslings WR; Blom DJ; de Waard-Siebinga I; van Beelen E; Claas FH; Jager MJ; Gorter A
Invest Ophthalmol Vis Sci; 1996 Aug; 37(9):1884-91. PubMed ID: 8759358
[TBL] [Abstract][Full Text] [Related]
15. CD55 and CD59 expression protects HER2-overexpressing breast cancer cells from trastuzumab-induced complement-dependent cytotoxicity.
Wang Y; Yang YJ; Wang Z; Liao J; Liu M; Zhong XR; Zheng H; Wang YP
Oncol Lett; 2017 Sep; 14(3):2961-2969. PubMed ID: 28928834
[TBL] [Abstract][Full Text] [Related]
16. Effect of periodontopathogen lipopolysaccharides and proinflammatory cytokines on CD46, CD55, and CD59 gene/protein expression by oral epithelial cells.
Mahtout H; Curt S; Chandad F; Rouabhia M; Grenier D
FEMS Immunol Med Microbiol; 2011 Aug; 62(3):295-303. PubMed ID: 21545652
[TBL] [Abstract][Full Text] [Related]
17. Levels of expression of complement regulatory proteins CD46, CD55 and CD59 on resting and activated human peripheral blood leucocytes.
Christmas SE; de la Mata Espinosa CT; Halliday D; Buxton CA; Cummerson JA; Johnson PM
Immunology; 2006 Dec; 119(4):522-8. PubMed ID: 16999828
[TBL] [Abstract][Full Text] [Related]
18. Adeno-associated virus mediated delivery of an engineered protein that combines the complement inhibitory properties of CD46, CD55 and CD59.
Leaderer D; Cashman SM; Kumar-Singh R
J Gene Med; 2015; 17(6-7):101-15. PubMed ID: 25917932
[TBL] [Abstract][Full Text] [Related]
19. 6 months versus 12 months of adjuvant trastuzumab for patients with HER2-positive early breast cancer (PHARE): a randomised phase 3 trial.
Pivot X; Romieu G; Debled M; Pierga JY; Kerbrat P; Bachelot T; Lortholary A; Espié M; Fumoleau P; Serin D; Jacquin JP; Jouannaud C; Rios M; Abadie-Lacourtoisie S; Tubiana-Mathieu N; Cany L; Catala S; Khayat D; Pauporté I; Kramar A;
Lancet Oncol; 2013 Jul; 14(8):741-8. PubMed ID: 23764181
[TBL] [Abstract][Full Text] [Related]
20. Prognostic factors for recurrence-free survival in patients with HER2-positive early-stage breast cancer treated with adjuvant trastuzumab.
Tonyali O; Coskun U; Sener N; Inanc M; Akman T; Ulas A; Yazilitas D; Bal O; Kucukoner M; Yildirim Ozdemir N; Demirci U; Gunaydin Y; Yildiz R; Karaca H; Umit Unal O; Gumus M; Benekli M; Buyukberber S
Onkologie; 2013; 36(10):554-8. PubMed ID: 24107908
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
